Suppr超能文献

袋状结肠炎中与益生菌疗法(VSL#3)相关的细菌和真菌微生物群。

Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.

作者信息

Kühbacher T, Ott S J, Helwig U, Mimura T, Rizzello F, Kleessen B, Gionchetti P, Blaut M, Campieri M, Fölsch U R, Kamm M A, Schreiber S

机构信息

Department of General Internal Medicine, Kiel, Germany.

出版信息

Gut. 2006 Jun;55(6):833-41. doi: 10.1136/gut.2005.078303. Epub 2006 Jan 9.

Abstract

BACKGROUND

The intestinal microbiota plays a critical role in the pathophysiology of pouchitis, a major complication after ileal pouch anal anastomosis in patients with ulcerative colitis. Recently, controlled trials have demonstrated that probiotics are effective in maintenance of remission in pouchitis patients. However, the mechanism by which therapy with probiotics works remains elusive. This study explores the role of the bacterial and fungal flora in a controlled trial for maintenance of remission in pouchitis patients with the probiotic VSL#3 compound.

METHODS

The mucosa associated pouch microbiota was investigated before and after therapy with VSL#3 by analysis of endoscopic biopsies using ribosomal DNA/RNA based community fingerprint analysis, clone libraries, real time polymerase chain reaction (PCR), and fluorescence in situ hybridisation. Patients were recruited from a placebo controlled remission maintenance trial with VSL#3.

RESULTS

Patients who developed pouchitis while treated with placebo had low bacterial and high fungal diversity. Bacterial diversity was increased and fungal diversity was reduced in patients in remission maintained with VSL#3 (p = 0.001). Real time PCR experiments demonstrated that VSL#3 increased the total number of bacterial cells (p = 0.002) and modified the spectrum of bacteria towards anaerobic species. Taxa specific clone libraries for Lactobacilli and Bifidobacteria showed that the richness and spectrum of these bacteria were altered under probiotic therapy.

CONCLUSIONS

Probiotic therapy with VSL#3 increases the total number of intestinal bacterial cells as well as the richness and diversity of the bacterial microbiota, especially the anaerobic flora. The diversity of the fungal flora is repressed. Restoration of the integrity of a "protective" intestinal mucosa related microbiota could therefore be a potential mechanism of probiotic bacteria in inflammatory barrier diseases of the lower gastrointestinal tract.

摘要

背景

肠道微生物群在袋炎的病理生理学中起关键作用,袋炎是溃疡性结肠炎患者回肠袋肛管吻合术后的一种主要并发症。最近,对照试验表明益生菌对维持袋炎患者的缓解有效。然而,益生菌治疗起作用的机制仍不清楚。本研究在一项使用益生菌VSL#3化合物维持袋炎患者缓解的对照试验中,探讨细菌和真菌菌群的作用。

方法

通过基于核糖体DNA/RNA的群落指纹分析、克隆文库、实时聚合酶链反应(PCR)和荧光原位杂交分析内镜活检样本,研究VSL#3治疗前后与袋相关的黏膜微生物群。患者来自一项使用VSL#3的安慰剂对照缓解维持试验。

结果

在接受安慰剂治疗时发生袋炎的患者细菌多样性低而真菌多样性高。用VSL#3维持缓解的患者细菌多样性增加而真菌多样性降低(p = 0.001)。实时PCR实验表明,VSL#3增加了细菌细胞总数(p = 0.002),并使细菌谱向厌氧菌种改变。针对乳酸杆菌和双歧杆菌的分类群特异性克隆文库显示,在益生菌治疗下这些细菌的丰富度和谱发生了改变。

结论

用VSL#3进行益生菌治疗可增加肠道细菌细胞总数以及细菌微生物群的丰富度和多样性,尤其是厌氧菌群。真菌菌群的多样性受到抑制。因此,恢复与“保护性”肠道黏膜相关微生物群的完整性可能是益生菌在下消化道炎症性屏障疾病中的潜在作用机制。

相似文献

4
The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis.抗生素和益生菌在治疗袋炎方面的治疗潜力。
Expert Rev Gastroenterol Hepatol. 2015;9(9):1175-81. doi: 10.1586/17474124.2015.1072046. Epub 2015 Jul 25.
5
High-dose probiotics for the treatment of active pouchitis.高剂量益生菌治疗活动性储袋炎。
Dis Colon Rectum. 2007 Dec;50(12):2075-82; discussion 2082-4. doi: 10.1007/s10350-007-9068-4. Epub 2007 Oct 13.
9
Role of probiotics in the management of pouchitis.益生菌在袋炎管理中的作用。
Curr Pharm Des. 2014;20(28):4561-4. doi: 10.2174/13816128113196660724.

引用本文的文献

7
Pouchitis: pathophysiology and management.袋炎:病理生理学与管理
Nat Rev Gastroenterol Hepatol. 2024 Jul;21(7):463-476. doi: 10.1038/s41575-024-00920-5. Epub 2024 Apr 25.
8
Development and management of gastrointestinal symptoms in long-term COVID-19.长期新冠患者胃肠道症状的发展与管理
Front Microbiol. 2023 Dec 14;14:1278479. doi: 10.3389/fmicb.2023.1278479. eCollection 2023.

本文引用的文献

10

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验